Intrathecal Pumps Market 2021-2026: Research Report Size, Share And Trends

In 2020, the global intrathecal pumps market was valued at USD 189.7 million, with a compound yearly growth rate (CAGR) of 5.1 percent predicted from 2021 to 2028. Because of the expanding prevalence of cancer and other chronic pain problems, product demand is increasing. Furthermore, the expanding elderly population, as well as the elimination or reduced usage of alternative pain drugs, are driving market expansion. Chronic pain is the leading cause of disability and is associated with significant financial and social costs. According to the National Cancer Institute, new cancer diagnoses occur at a rate of 442.4 per 100,000 men and women each year. Intrathecal pumps are better than oral pharmaceuticals because they work directly in the CSF, allowing drugs to be absorbed faster and more effectively.

In addition, when compared to oral drugs, they require substantially less medication. When compared to oral treatments, pain pumps require around 1/300 the amount of medication. Increased potency, less systemic exposure, and the dose necessary to elicit the targeted pharmacologic effect are projected to drive Intrathecal Pumps Market expansion. For example, Flowonix Medicals produced a 40 mL pump for providing medications into the intrathecal space; the delivery device uses a valve-gated, pressure-driven delivery mechanism and has a battery life of more than 10 years, potentially reducing the need for future surgical procedures.

Intrathecal drug or medication delivery improves comfort and relieves chronic pain, reducing the need for opioids and allowing patients to resume their lives. Intrathecal medication delivery is used to treat pain caused by disorders like the failed spine and neck surgeries, chronic back pain, neck discomfort, and stomach pain. It also helps to reduce spasticity (muscle rigidity and spasms) and other similar problems. The Food and Drug Administration (FDA) in the United States has not yet approved all intrathecal pumps for use. The Food and Drug Administration (FDA) has issued a warning to healthcare providers and patients about the dangers of using medications that have not been approved by the FDA. Drugs that are approved for intrathecal administration must meet additional safety standards.